Oramed Pharmaceuticals Stock Buy Hold or Sell Recommendation
| ORMP Stock | USD 2.37 0.02 0.85% |
Given the investment horizon of 90 days and your typical level of risk aversion, our recommendation regarding Oramed Pharmaceuticals is 'Strong Sell'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Oramed Pharmaceuticals given historical horizon and risk tolerance towards Oramed Pharmaceuticals. When Macroaxis issues a 'buy' or 'sell' recommendation for Oramed Pharmaceuticals, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Oramed Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Oramed Stock, please use our How to Invest in Oramed Pharmaceuticals guide. Note, we conduct extensive research on individual companies such as Oramed and provide practical buy, sell, or hold advice based on investors' constraints. Oramed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
Oramed |
Execute Oramed Pharmaceuticals Buy or Sell Advice
The Oramed recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Oramed Pharmaceuticals. Macroaxis does not own or have any residual interests in Oramed Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Oramed Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Unstable | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Hold | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Oramed Pharmaceuticals Trading Alerts and Improvement Suggestions
| Oramed Pharmaceuticals currently holds about 133.91 M in cash with (10.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.45, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from news.google.com: Oramed Pharmaceuticals Share Price Passes Below 200-Day Moving Average - Should You Sell - MarketBeat |
Oramed Pharmaceuticals Returns Distribution Density
The distribution of Oramed Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Oramed Pharmaceuticals' future price movements. The chart of the probability distribution of Oramed Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Oramed Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Oramed Pharmaceuticals returns is essential to provide solid investment advice for Oramed Pharmaceuticals.
| Mean Return | -0.04 | Value At Risk | -3.33 | Potential Upside | 3.40 | Standard Deviation | 2.33 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Oramed Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Oramed Stock Institutional Investors
The Oramed Pharmaceuticals' institutional investors refer to entities that pool money to purchase Oramed Pharmaceuticals' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | Squarepoint Ops Llc | 2024-06-30 | 81.8 K | State Street Corp | 2024-06-30 | 59.3 K | Jane Street Group Llc | 2024-06-30 | 56.1 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 48.8 K | Lpl Financial Corp | 2024-09-30 | 38.7 K | Pnc Financial Services Group Inc | 2024-09-30 | 26.2 K | Wells Fargo & Co | 2024-06-30 | 25.6 K | Geode Capital Management, Llc | 2024-09-30 | 25.5 K | Xtx Topco Ltd | 2024-09-30 | 24.7 K | Bml Capital Management Llc | 2024-09-30 | 2.2 M | Murchinson Ltd. | 2024-06-30 | 1.7 M |
Oramed Pharmaceuticals Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (1.7M) | 16.0M | 57.9M | 13.0M | (31.4M) | (29.8M) | |
| Free Cash Flow | (13.0M) | (12.5M) | (21.6M) | (28.4M) | (10.5M) | (10.0M) | |
| Change In Working Capital | 290K | (3.2M) | (1.3M) | (943K) | (2.7M) | (2.6M) | |
| Begin Period Cash Flow | 5.0M | 3.3M | 19.3M | 27.5M | 40.5M | 42.5M | |
| Capital Expenditures | 15K | 82K | 375K | 496K | 254K | 266.7K | |
| Total Cash From Operating Activities | (12.9M) | (12.4M) | (21.2M) | (27.9M) | (10.3M) | (9.8M) | |
| Net Income | (14.4M) | (11.5M) | (23.0M) | (37.8M) | 5.5M | 5.8M | |
| Other Cashflows From Financing Activities | 11.3M | 13K | 22.9M | (721K) | (829.2K) | (787.7K) | |
| Other Non Cash Items | 55K | 38K | 1.0M | (778K) | 1.5M | 1.5M | |
| End Period Cash Flow | 3.3M | 19.3M | 77.2M | 40.5M | 9.1M | 11.2M | |
| Depreciation | 8K | 7K | 77K | 58K | 196K | 205.8K | |
| Stock Based Compensation | 808K | 1.2M | 2.7M | 11.5M | 4.2M | 2.2M |
Oramed Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Oramed Pharmaceuticals or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Oramed Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Oramed stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.05 | |
β | Beta against Dow Jones | 0.07 | |
σ | Overall volatility | 2.33 | |
Ir | Information ratio | -0.07 |
Oramed Pharmaceuticals Volatility Alert
Oramed Pharmaceuticals exhibits very low volatility with skewness of 0.13 and kurtosis of 0.71. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Oramed Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Oramed Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Oramed Pharmaceuticals Fundamentals Vs Peers
Comparing Oramed Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Oramed Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Oramed Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Oramed Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Oramed Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Oramed Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Oramed Pharmaceuticals to competition |
| Fundamentals | Oramed Pharmaceuticals | Peer Average |
| Return On Equity | 0.0289 | -0.31 |
| Return On Asset | -0.0412 | -0.14 |
| Current Valuation | (47.14 M) | 16.62 B |
| Shares Outstanding | 40.77 M | 571.82 M |
| Shares Owned By Insiders | 10.62 % | 10.09 % |
| Shares Owned By Institutions | 17.32 % | 39.21 % |
| Number Of Shares Shorted | 313.9 K | 4.71 M |
| Price To Earning | (11.22) X | 28.72 X |
| Price To Book | 0.61 X | 9.51 X |
| Price To Sales | 141.54 X | 11.42 X |
| Revenue | 1.34 M | 9.43 B |
| Gross Profit | 2.7 M | 27.38 B |
| EBITDA | (12.85 M) | 3.9 B |
| Net Income | 5.53 M | 570.98 M |
| Cash And Equivalents | 133.91 M | 2.7 B |
| Cash Per Share | 3.45 X | 5.01 X |
| Total Debt | 51.01 M | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 21.01 X | 2.16 X |
| Book Value Per Share | 3.89 X | 1.93 K |
| Cash Flow From Operations | (10.29 M) | 971.22 M |
| Short Ratio | 3.80 X | 4.00 X |
| Earnings Per Share | 0.51 X | 3.12 X |
| Target Price | 3.25 | |
| Beta | 1.77 | -0.15 |
| Market Capitalization | 94.58 M | 19.03 B |
| Total Asset | 220.55 M | 29.47 B |
| Retained Earnings | (157.56 M) | 9.33 B |
| Working Capital | 109.37 M | 1.48 B |
| Current Asset | 31 M | 9.34 B |
| Current Liabilities | 4 M | 7.9 B |
| Net Asset | 220.55 M |
Note: Acquisition by Joshua Hexter of 30000 shares of Oramed Pharmaceuticals subject to Rule 16b-3 [view details]
Oramed Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Oramed . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Oramed Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Oramed Pharmaceuticals? Buying financial instruments such as Oramed Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Oramed Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Shipping Containers Thematic Idea Now
Shipping Containers
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Shipping Containers theme has 16 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Shipping Containers Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Oramed Stock Analysis
When running Oramed Pharmaceuticals' price analysis, check to measure Oramed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oramed Pharmaceuticals is operating at the current time. Most of Oramed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oramed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oramed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oramed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.